Citadel Advisors
KROS icon

Citadel Advisors’s Keros Therapeutics KROS Stock Holding History

Citadel Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.24M Sell
396,098
-10,568
-3% -$118K ﹤0.01% 5019
2026
Q1 		$4.49M Sell
406,666
-65,854
-14% -$1.02M ﹤0.01% 4521
2025
Q4 		$9.62M Buy
472,520
+296,376
+168% +$5.2M ﹤0.01% 3301
2025
Q3 		$2.79M Buy
176,144
+153,246
+669% +$2.26M ﹤0.01% 5437
2025
Q2 		$306K Sell
22,898
-168,711
-88% -$2.28M ﹤0.01% 9771
2025
Q1 		$1.95M Sell
191,609
-599,500
-76% -$6.96M ﹤0.01% 5576
2024
Q4 		$12.5M Buy
791,109
+86,186
+12% +$4.48M ﹤0.01% 2696
2024
Q3 		$40.9M Buy
704,923
+294,439
+72% +$14.5M 0.01% 1401
2024
Q2 		$18.8M Sell
410,484
-39,794
-9% -$2.14M ﹤0.01% 2063
2024
Q1 		$29.8M Sell
450,278
-309,890
-41% -$18.4M 0.01% 1669
2023
Q4 		$30.2M Buy
760,168
+355,019
+88% +$11.1M 0.01% 1615
2023
Q3 		$12.9M Buy
405,149
+77,349
+24% +$2.89M ﹤0.01% 2363
2023
Q2 		$13.2M Sell
327,800
-43,683
-12% -$1.91M ﹤0.01% 2341
2023
Q1 		$15.9M Sell
371,483
-33,988
-8% -$1.72M ﹤0.01% 2194
2022
Q4 		$19.5M Sell
405,471
-22,636
-5% -$1.06M ﹤0.01% 1996
2022
Q3 		$16.1M Buy
428,107
+73,753
+21% +$2.56M ﹤0.01% 2128
2022
Q2 		$9.79M Buy
354,354
+74,193
+26% +$3.26M ﹤0.01% 2716
2022
Q1 		$15.2M Buy
280,161
+3,059
+1% +$157K ﹤0.01% 2342
2021
Q4 		$16.2M Buy
277,102
+2,777
+1% +$138K ﹤0.01% 2300
2021
Q3 		$10.9M Buy
274,325
+156,377
+133% +$5.57M ﹤0.01% 2945
2021
Q2 		$5.01M Sell
117,948
-9,977
-8% -$540K ﹤0.01% 4429
2021
Q1 		$7.87M Sell
127,925
-141,318
-52% -$8.95M ﹤0.01% 3361
2020
Q4 		$19M Buy
+269,243
New +$17M ﹤0.01% 1858
2020
Q3 		– Sell
-157,333
Closed -$5.9M – 10435
2020
Q2 		$5.9M Buy
+157,333
New +$4.85M ﹤0.01% 2861

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Citadel Advisors's KROS Position: Q2 2026 in Review

Citadel Advisors reduced its Keros Therapeutics (KROS) stake by 2.6% in Q2 2026, selling an estimated $118K and leaving 396,098 shares worth $4.24M. The position accounts for ﹤0.01% of the portfolio, ranked #5019.

Citadel Advisors first reported a position in KROS in Q2 2020 and has held it in 24 quarters since. The position peaked at $40.9M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Citadel Advisors held 396,098 shares of Keros Therapeutics worth $4.24M as of Q2 2026.
  • Citadel Advisors sold 10,568 Keros Therapeutics shares in Q2 2026, an estimated $118K.
  • Keros Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5019 holding.
  • Citadel Advisors first reported a position in Keros Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Keros Therapeutics position peaked at $40.9M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.